Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Incyte Corporation

Market Cap 19.62B 17.11B 15.85B 14.83B 27.82B 1,852B 27.99B 188B 72.85B 911B 73.66B 72.08B 3,164B P/E 2026 *
14.8x
P/E 2027 * 12.5x
Enterprise Value 14.64B 12.77B 11.82B 11.07B 20.76B 1,381B 20.88B 140B 54.36B 680B 54.96B 53.78B 2,361B EV / Sales 2026 *
2.6x
EV / Sales 2027 * 2.05x
Free-Float
98.11%
Yield 2026 *
-
Yield 2027 * -
1 day-0.78%
1 week-9.50%
Current month+1.53%
1 month+1.17%
3 months+8.20%
6 months-4.35%
Current year-0.56%
1 week 96.09
Extreme 96.09
107.98
1 month 92.18
Extreme 92.18
110.34
Current year 89.25
Extreme 89.25
112.29
1 year 66.74
Extreme 66.7401
112.29
3 years 50.27
Extreme 50.27
112.29
5 years 50.27
Extreme 50.27
112.29
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 2025-06-25
Director of Finance/CFO 57 2026-05-03
President 62 2023-06-04
Director TitleAgeSince
Chairman 59 2025-06-25
Director/Board Member 72 2015-01-19
Director/Board Member 64 2015-01-19
Date Insider Type Main position Quantity % Market Cap.
06-07Free

Director

7,753 0.0039%
06-07
FBS Associates LLC
OtherCompany 0 0%
06-07
Baker Bros. Advisors LP
FreeCompany 15,506 0.0078%
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-9.50%+43.47%+59.06% 19.62B
+0.33%-0.36%+19.66%-21.92% 62.05B
+0.20%-9.17%+58.54%+194.67% 54.52B
-3.92%+37.40%+37.40%+37.40% 41.55B
+7.62%+8.19%-51.58%-58.97% 39.06B
-1.05%-1.73%+54.74%-33.09% 29.02B
+3.50%+28.15%+146.95%-48.51% 25.38B
+1.74%-0.39%-1.99%+126.64% 16.89B
-0.05%+0.23%+61.48%+104.74% 15.89B
-1.66%-0.79%+58.81%+301.15% 12.98B
Average +0.59%+2.31%+42.75%+66.12% 31.7B
Weighted average by Cap. +0.68%+1.58%+37.32%+47.90%

Financials

2026 *2027 *
Net sales 5.63B 4.91B 4.54B 4.25B 7.98B 531B 8.03B 53.91B 20.89B 261B 21.13B 20.67B 908B 6.24B 5.44B 5.04B 4.72B 8.85B 589B 8.9B 59.81B 23.18B 290B 23.44B 22.93B 1,007B
Net income 1.38B 1.2B 1.11B 1.04B 1.96B 130B 1.97B 13.22B 5.12B 64.08B 5.18B 5.07B 222B 1.65B 1.44B 1.33B 1.25B 2.34B 156B 2.35B 15.8B 6.12B 76.61B 6.19B 6.06B 266B
Net Debt -4.98B -4.34B -4.02B -3.77B -7.06B -470B -7.11B -47.73B -18.5B -231B -18.7B -18.3B -803B -6.83B -5.96B -5.52B -5.16B -9.68B -644B -9.74B -65.43B -25.36B -317B -25.64B -25.09B -1,101B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
26-06-18 98.22 $ -0.78% 4,058,623
26-06-17 98.99 $ -0.76% 1,716,059
26-06-16 99.75 $ -2.19% 1,556,318
26-06-15 101.98 $ -6.04% 2,815,109
26-06-12 108.53 $ +0.65% 1,488,907
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
98.22USD
Average target price
109.35USD
Spread / Average Target
+11.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!